Some myths about PSA screening mskcc.org/news/myths-abo…

Andreas Røder Tyler Seibert MD PhD Tony Collier BEM Ed Stupple JAMA Richard Martin Caroline Moore Hashim U. Ahmed Andrew Vickers Matt Hobbs PCF Science PSA is the best liquid marker in the history of oncology. Nearly everyone should get a baseline around age 45-55, which rules out ~75% if the population with a cheap easy test. THEN use MRI/markers to avoid overdx and basically never tx GG1 and the harms fall dramatically.

Summarized the ProScreen trial today at #AACR24 in a fun session with Andrew Vickers and the great Ruth Etzioni. Awesome to have stars Eric Klein Petros Grivas Prostate Cancer Foundation leadership join us. Prostate cancer screening done the right way keeps getting better for our patients.

Thank you Freddie Hamdy . Been trying to get 'csPCa' out of the literature for years....

Join biostatician Dr. Andrew Vickers (Andrew Vickers) for an oral session about myths about #PSA and #prostatecancer screening at #AACR24 (@AACR) today at 2:31 PST. Learn more: bit.ly/4al0E3h

Results of Finnish Proscreen RCT. PSA => 4Kscore => MRI: 30% reduction in MRIs, 85% of cancers were high grade (CoI: I get royalties from 4K) jamanetwork.com/journals/jama/…

Although this is not so much a problem in itself if we changed guidelines so that the sort of patients recategorized GG1 to GG2 were put on AS

Nice. I wonder how long it will take them to work out 1) banning responder analysis 2) using baselines as a covariate rather than as a reference point will make a huge contribution to efficiency. researchportal.lih.lu/en/publication… raps.org/News-and-Artic…

This 'reassuring' MRI paper is a 'straw man' argument. The overtreatment argument is NOT 'many patients get downgraded on RP', it that MRI finds high-grade cancers in groups known to have very low long-term mortality. sciencedirect.com/science/articl…

NEJM has not one, but two studies on colorectal cancer screening that report only sensitivity and specificity of a new test. I have zero idea how to interpret the results: are they good tests or bad? #ClinicallyRelevantStatistics nejm.org/doi/full/10.10…

Prostate cancer associated with high incidence of mental health problems. Patients with 3+3 not at importantly lower risk. Another argument for redesignating pattern 3 to premalignant. academic.oup.com/jnci/article/1…

TL;DR version: MRI changed how we found prostate cancer, but we didn't update our pathology or treatment guidelines

“Our conclusion was that the amount of pattern 3 in men with grade groups 2, 3, and 4 is not predictive of oncologic outcome once you know the amount of [pattern] 4,” says Andrew Vickers, PhD. Andrew Vickers Memorial Sloan Kettering Cancer Center #pcsm #urology

Watch now: urologytimes.com/view/expert-gl…

Now published in Journal of Urology by UrologyMSK Vincent Laudone John P. Mulhall MD et al.:
Do phosphodiesterase type 5 inhibitors increase the risk of biochemical recurrence after radical prostatectomy?
auajournals.org/doi/10.1097/JU…

The UK has an 'informed choice' program for PSA screening for prostate cancer: a man can get a PSA after shared decision-making with his doctor. Whatever you think of that, surely no justification in allowing this for men over 75?

Grateful to Andrew Vickers for setting the stage and recognizing our work on the importance of evolving grading guidelines to align with modern diagnostic pathways. Romain Diamand Thierry Roumeguere Peltier Alexandre Institut Jules Bordet Instituut Memorial Sloan Kettering Cancer Center bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

All models are wrong and yours are useless!

In case you missed my talk yesterday on how to make clinical prediction tools useful for patients, you can read all about it here.

Enjoy!

doi.org/10.1038/s41698…

Worth repeating: because cancer screening is associated with overdiagnosis, a marker to help cancer screening must differentially detect aggressive disease ncbi.nlm.nih.gov/pmc/articles/P…

Everything single study reporting on the ascertainment of minimal important differences in patient-reported outcome measures is flawed because there is no such thing as a scale-dependent, minimal important difference

We take a pragmatic approach to improving the 4kscore for prostate cancer screening in Black men. Thank you sanoj punnen Andrew Vickers for your mentorship and great working w Daniel Sjoberg Dr. Brandon Mahal 🏁 Jamie Thomas